annual EBITDA:
$40.79M-$60.04M(-59.54%)Summary
- As of today (June 2, 2025), LGND annual EBITDA is $40.79 million, with the most recent change of -$60.04 million (-59.54%) on December 31, 2024.
- During the last 3 years, LGND annual EBITDA has fallen by -$101.98 million (-71.43%).
- LGND annual EBITDA is now -95.34% below its all-time high of $876.12 million, reached on December 31, 2019.
Performance
LGND EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$40.54M-$10.85M(-36.55%)Summary
- As of today (June 2, 2025), LGND quarterly EBITDA is -$40.54 million, with the most recent change of -$10.85 million (-36.55%) on March 31, 2025.
- Over the past year, LGND quarterly EBITDA has dropped by -$162.90 million (-133.14%).
- LGND quarterly EBITDA is now -104.73% below its all-time high of $857.90 million, reached on March 31, 2019.
Performance
LGND quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$122.11M-$162.90M(-399.35%)Summary
- As of today (June 2, 2025), LGND TTM EBITDA is -$122.11 million, with the most recent change of -$162.90 million (-399.35%) on March 31, 2025.
- Over the past year, LGND TTM EBITDA has dropped by -$280.02 million (-177.32%).
- LGND TTM EBITDA is now -111.82% below its all-time high of $1.03 billion, reached on March 31, 2019.
Performance
LGND TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
LGND EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -59.5% | -133.1% | -177.3% |
| 3 y3 years | -71.4% | -866.5% | -199.0% |
| 5 y5 years | -95.3% | -161.8% | -4571.1% |
LGND EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -71.4% | at low | -133.1% | +26.6% | -177.3% | at low |
| 5 y | 5-year | -95.3% | at low | -133.1% | +26.6% | -177.3% | at low |
| alltime | all time | -95.3% | +142.4% | -104.7% | +44.6% | -111.8% | at low |
LGND EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$40.54M(+36.6%) | -$122.11M(-399.4%) |
| Dec 2024 | $40.79M(-59.5%) | -$29.69M(-974.3%) | $40.79M(-57.8%) |
| Sep 2024 | - | $3.40M(-106.1%) | $96.62M(+7.7%) |
| Jun 2024 | - | -$55.27M(-145.2%) | $89.70M(-43.2%) |
| Mar 2024 | - | $122.35M(+368.0%) | $157.91M(+56.6%) |
| Dec 2023 | $100.84M(+12.9%) | $26.14M(-840.2%) | $100.84M(-8.6%) |
| Sep 2023 | - | -$3.53M(-127.3%) | $110.37M(-21.2%) |
| Jun 2023 | - | $12.95M(-80.2%) | $140.09M(-6.2%) |
| Mar 2023 | - | $65.28M(+83.0%) | $149.33M(+67.1%) |
| Dec 2022 | $89.34M(-37.4%) | $35.68M(+36.2%) | $89.34M(+0.4%) |
| Sep 2022 | - | $26.19M(+18.1%) | $88.96M(-6.4%) |
| Jun 2022 | - | $22.19M(+319.5%) | $95.08M(-22.9%) |
| Mar 2022 | - | $5.29M(-85.0%) | $123.37M(-13.6%) |
| Dec 2021 | $142.77M(+151.9%) | $35.29M(+9.2%) | $142.77M(+0.6%) |
| Sep 2021 | - | $32.31M(-36.0%) | $141.88M(+30.4%) |
| Jun 2021 | - | $50.48M(+104.5%) | $108.77M(+12.3%) |
| Mar 2021 | - | $24.69M(-28.2%) | $96.85M(+70.9%) |
| Dec 2020 | $56.67M(-93.5%) | $34.40M(-4427.2%) | $56.67M(+26.0%) |
| Sep 2020 | - | -$795.00K(-102.1%) | $44.97M(+3.5%) |
| Jun 2020 | - | $38.55M(-348.9%) | $43.43M(+1490.2%) |
| Mar 2020 | - | -$15.49M(-168.2%) | $2.73M(-99.7%) |
| Dec 2019 | $876.12M(+269.0%) | $22.70M(-1072.4%) | $876.12M(+6.8%) |
| Sep 2019 | - | -$2.33M(+8.9%) | $820.26M(-10.7%) |
| Jun 2019 | - | -$2.14M(-100.2%) | $918.74M(-11.1%) |
| Mar 2019 | - | $857.90M(-2686.9%) | $1.03B(+335.2%) |
| Dec 2018 | $237.40M(+186.7%) | -$33.16M(-134.5%) | $237.40M(-23.1%) |
| Sep 2018 | - | $96.15M(-14.4%) | $308.79M(+33.8%) |
| Jun 2018 | - | $112.34M(+81.0%) | $230.80M(+73.8%) |
| Mar 2018 | - | $62.07M(+62.4%) | $132.81M(+58.2%) |
| Dec 2017 | $82.81M(+158.0%) | $38.23M(+110.5%) | $83.94M(+86.8%) |
| Sep 2017 | - | $18.16M(+26.6%) | $44.95M(+27.7%) |
| Jun 2017 | - | $14.35M(+8.7%) | $35.18M(+27.4%) |
| Mar 2017 | - | $13.20M(-1836.2%) | $27.62M(-13.9%) |
| Dec 2016 | $32.09M(+7.1%) | -$760.00K(-109.0%) | $32.09M(-26.7%) |
| Sep 2016 | - | $8.40M(+23.9%) | $43.77M(-2.6%) |
| Jun 2016 | - | $6.78M(-61.6%) | $44.96M(+3.6%) |
| Mar 2016 | - | $17.67M(+61.9%) | $43.40M(+44.9%) |
| Dec 2015 | $29.96M(+28.2%) | $10.92M(+13.9%) | $29.95M(+0.2%) |
| Sep 2015 | - | $9.59M(+83.3%) | $29.89M(+21.1%) |
| Jun 2015 | - | $5.23M(+23.9%) | $24.68M(+14.2%) |
| Mar 2015 | - | $4.22M(-61.1%) | $21.62M(-7.5%) |
| Dec 2014 | $23.37M(+25.3%) | $10.86M(+148.2%) | $23.37M(+18.1%) |
| Sep 2014 | - | $4.38M(+102.3%) | $19.79M(+2.1%) |
| Jun 2014 | - | $2.16M(-63.8%) | $19.38M(-2.7%) |
| Mar 2014 | - | $5.97M(-18.0%) | $19.93M(+6.9%) |
| Dec 2013 | $18.65M(+373.0%) | $7.28M(+83.7%) | $18.64M(+11.4%) |
| Sep 2013 | - | $3.96M(+46.5%) | $16.74M(+37.8%) |
| Jun 2013 | - | $2.71M(-42.3%) | $12.15M(+39.6%) |
| Mar 2013 | - | $4.69M(-12.8%) | $8.71M(+120.9%) |
| Dec 2012 | $3.94M(+29.5%) | $5.38M(-963.2%) | $3.94M(-6.4%) |
| Sep 2012 | - | -$623.00K(-15.7%) | $4.21M(+0.5%) |
| Jun 2012 | - | -$739.00K(+898.6%) | $4.19M(-31.4%) |
| Mar 2012 | - | -$74.00K(-101.3%) | $6.11M(+99.6%) |
| Dec 2011 | $3.04M(-123.2%) | $5.65M(-975.8%) | $3.06M(-175.3%) |
| Sep 2011 | - | -$645.00K(-154.8%) | -$4.06M(-71.3%) |
| Jun 2011 | - | $1.18M(-137.7%) | -$14.18M(-0.9%) |
| Mar 2011 | - | -$3.12M(+111.9%) | -$14.30M(+8.9%) |
| Dec 2010 | -$13.13M(+103.0%) | -$1.47M(-86.3%) | -$13.13M(+33.3%) |
| Sep 2010 | - | -$10.76M(-1123.7%) | -$9.85M(-455.9%) |
| Jun 2010 | - | $1.05M(-153.8%) | $2.77M(-242.0%) |
| Mar 2010 | - | -$1.95M(-207.8%) | -$1.95M(-69.9%) |
| Dec 2009 | -$6.47M | $1.81M(-2.5%) | -$6.46M(-92.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2009 | - | $1.86M(-150.7%) | -$81.46M(-7.9%) |
| Jun 2009 | - | -$3.66M(-43.4%) | -$88.43M(-2.2%) |
| Mar 2009 | - | -$6.47M(-91.2%) | -$90.40M(-4.9%) |
| Dec 2008 | -$96.26M(+88.7%) | -$73.19M(+1333.1%) | -$95.08M(+323.0%) |
| Sep 2008 | - | -$5.11M(-9.3%) | -$22.48M(-12.5%) |
| Jun 2008 | - | -$5.63M(-49.5%) | -$25.69M(-23.3%) |
| Mar 2008 | - | -$11.15M(+1795.9%) | -$33.49M(-33.6%) |
| Dec 2007 | -$51.02M(-17.5%) | -$588.00K(-92.9%) | -$50.47M(-28.4%) |
| Sep 2007 | - | -$8.32M(-38.0%) | -$70.45M(-12.4%) |
| Jun 2007 | - | -$13.43M(-52.3%) | -$80.41M(+0.0%) |
| Mar 2007 | - | -$28.13M(+36.8%) | -$80.41M(+30.0%) |
| Dec 2006 | -$61.86M(+148.2%) | -$20.57M(+12.5%) | -$61.86M(+3.0%) |
| Sep 2006 | - | -$18.28M(+36.2%) | -$60.08M(+44.3%) |
| Jun 2006 | - | -$13.43M(+40.0%) | -$41.64M(+38.8%) |
| Mar 2006 | - | -$9.59M(-49.0%) | -$29.99M(-5.4%) |
| Dec 2005 | -$24.92M(>+9900.0%) | -$18.78M(<-9900.0%) | -$31.72M(-207.7%) |
| Sep 2005 | - | $158.00K(-108.9%) | $29.44M(+67.8%) |
| Jun 2005 | - | -$1.78M(-84.2%) | $17.55M(+355.0%) |
| Mar 2005 | - | -$11.31M(-126.7%) | $3.86M(-3773.3%) |
| Dec 2004 | -$105.00K(-99.8%) | $42.38M(-461.1%) | -$105.00K(-99.9%) |
| Sep 2004 | - | -$11.74M(-24.2%) | -$83.04M(+9.3%) |
| Jun 2004 | - | -$15.48M(+1.3%) | -$75.97M(+15.1%) |
| Mar 2004 | - | -$15.27M(-62.3%) | -$66.03M(+10.6%) |
| Dec 2003 | -$59.69M(+69.9%) | -$40.56M(+769.8%) | -$59.69M(+46.4%) |
| Sep 2003 | - | -$4.66M(-15.7%) | -$40.77M(-0.9%) |
| Jun 2003 | - | -$5.53M(-38.1%) | -$41.12M(-5.1%) |
| Mar 2003 | - | -$8.94M(-58.7%) | -$43.34M(+23.4%) |
| Dec 2002 | -$35.13M(+112.1%) | -$21.64M(+331.6%) | -$35.13M(+138.8%) |
| Sep 2002 | - | -$5.01M(-35.4%) | -$14.71M(+17.3%) |
| Jun 2002 | - | -$7.76M(+972.8%) | -$12.54M(+18.1%) |
| Mar 2002 | - | -$723.00K(-40.5%) | -$10.62M(-35.9%) |
| Dec 2001 | -$16.56M(-57.1%) | -$1.22M(-57.3%) | -$16.56M(-28.2%) |
| Sep 2001 | - | -$2.85M(-51.1%) | -$23.07M(-24.7%) |
| Jun 2001 | - | -$5.83M(-12.6%) | -$30.66M(-10.8%) |
| Mar 2001 | - | -$6.67M(-13.7%) | -$34.38M(-1.3%) |
| Dec 2000 | -$38.64M(-28.7%) | -$7.72M(-26.0%) | -$34.84M(-20.4%) |
| Sep 2000 | - | -$10.44M(+9.3%) | -$43.78M(-1.3%) |
| Jun 2000 | - | -$9.55M(+33.9%) | -$44.38M(-8.0%) |
| Mar 2000 | - | -$7.13M(-57.2%) | -$48.23M(-4.9%) |
| Dec 1999 | -$54.19M(-16.8%) | -$16.66M(+51.0%) | -$50.70M(-13.8%) |
| Sep 1999 | - | -$11.04M(-17.6%) | -$58.84M(-6.5%) |
| Jun 1999 | - | -$13.40M(+39.6%) | -$62.90M(-1.6%) |
| Mar 1999 | - | -$9.60M(-61.3%) | -$63.90M(-1.8%) |
| Dec 1998 | -$65.10M(+210.0%) | -$24.80M(+64.2%) | -$65.10M(+64.8%) |
| Sep 1998 | - | -$15.10M(+4.9%) | -$39.50M(+22.7%) |
| Jun 1998 | - | -$14.40M(+33.3%) | -$32.20M(+29.3%) |
| Mar 1998 | - | -$10.80M(-1450.0%) | -$24.90M(+19.1%) |
| Dec 1997 | -$21.00M(-10.6%) | $800.00K(-110.3%) | -$20.90M(-29.9%) |
| Sep 1997 | - | -$7.80M(+9.9%) | -$29.80M(+22.1%) |
| Jun 1997 | - | -$7.10M(+4.4%) | -$24.40M(-2.4%) |
| Mar 1997 | - | -$6.80M(-16.0%) | -$25.00M(+7.8%) |
| Dec 1996 | -$23.50M(+10.8%) | -$8.10M(+237.5%) | -$23.20M(+8.9%) |
| Sep 1996 | - | -$2.40M(-68.8%) | -$21.30M(-17.1%) |
| Jun 1996 | - | -$7.70M(+54.0%) | -$25.70M(+104.0%) |
| Mar 1996 | - | -$5.00M(-19.4%) | -$12.60M(+14.5%) |
| Dec 1995 | -$21.20M(+15.2%) | -$6.20M(-8.8%) | -$11.00M(+34.1%) |
| Sep 1995 | - | -$6.80M(-225.9%) | -$8.20M(+41.4%) |
| Jun 1995 | - | $5.40M(-258.8%) | -$5.80M(-65.1%) |
| Mar 1995 | - | -$3.40M(0.0%) | -$16.60M(-9.8%) |
| Dec 1994 | -$18.40M | -$3.40M(-22.7%) | -$18.40M(+22.7%) |
| Sep 1994 | - | -$4.40M(-18.5%) | -$15.00M(+41.5%) |
| Jun 1994 | - | -$5.40M(+3.8%) | -$10.60M(+103.8%) |
| Mar 1994 | - | -$5.20M | -$5.20M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual EBITDA?
- What is the all time high annual EBITDA for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual EBITDA year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly EBITDA?
- What is the all time high quarterly EBITDA for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM EBITDA?
- What is the all time high TTM EBITDA for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual EBITDA?
The current annual EBITDA of LGND is $40.79M
What is the all time high annual EBITDA for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual EBITDA is $876.12M
What is Ligand Pharmaceuticals Incorporated annual EBITDA year-on-year change?
Over the past year, LGND annual EBITDA has changed by -$60.04M (-59.54%)
What is Ligand Pharmaceuticals Incorporated quarterly EBITDA?
The current quarterly EBITDA of LGND is -$40.54M
What is the all time high quarterly EBITDA for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly EBITDA is $857.90M
What is Ligand Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
Over the past year, LGND quarterly EBITDA has changed by -$162.90M (-133.14%)
What is Ligand Pharmaceuticals Incorporated TTM EBITDA?
The current TTM EBITDA of LGND is -$122.11M
What is the all time high TTM EBITDA for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM EBITDA is $1.03B
What is Ligand Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
Over the past year, LGND TTM EBITDA has changed by -$280.02M (-177.32%)